UnknownNot Applicable

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

United States, Georgia, Kenya2,000 participantsStarted 2021-01-05

Plain-language summary

During the study, members of different online and offline communities will be followed post COVID-19 vaccination. Injection-site (local) and systemic reaction data will be assessed on vaccination day and afterwards using either web surveys or personal communication, depending on study participant preference. Hypothesis to be tested: The safety profile and the magnitude and durability of immune responses to the COVID-19 vaccines as well as adverse reactions depend on health conditions, metabolism and microbiomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Individuals 18 or older at the time of consent * Intention to vaccinate and of being available for entire study period Exclusion Criteria: * Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.

What they're measuring

Adverse reactions/events

Timeframe: 10 days after any dose of study intervention.

Trial details

NCT IDNCT04832932

SponsorMebo Research, Inc.

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-01-05

View on ClinicalTrials.gov More COVID-19 Vaccines trials